WESPAC Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

WESPAC Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-222	Closed	-$233K	–	164
2024 Q2	$233K	Sell	222 -93	-30%	-$90.2K	0.18%	135
2024 Q1	$303K	Sell	315 -4	-1%	-$3.8K	0.18%	137
2023 Q4	$280K	Sell	319 -16	-5%	-$13.2K	0.19%	122
2023 Q3	$276K	Buy	+335	New	+$263K	0.21%	114
2023 Q2	–	Sell	-272	Closed	-$223K	–	129
2023 Q1	$223K	Buy	+272	New	+$205K	0.21%	98
2020 Q3	–	Sell	-339	Closed	-$211K	–	107
2020 Q2	$211K	Buy	+339	New	+$192K	0.24%	97
2016 Q1	–	Sell	-1,347	Closed	-$731K	–	121
2015 Q4	$731K	Buy	1,347 +516	+62%	+$280K	0.85%	56
2015 Q3	$387K	Sell	831 -313	-27%	-$168K	0.68%	45
2015 Q2	$584K	Buy	+1,144	New	+$558K	0.44%	73

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

WESPAC Advisors's REGN Position: Q3 2024 in Review

WESPAC Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q3 2024, closing a stake of 222 shares — an estimated $233K sold.

WESPAC Advisors first reported a position in REGN in Q2 2015 and held it in 9 quarters. The position peaked at $731K in Q4 2015. 1,391 funds tracked by Wall St. Rank hold REGN as of Q3 2024.

WESPAC Advisors reported no remaining Regeneron Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
WESPAC Advisors sold 222 Regeneron Pharmaceuticals shares in Q3 2024, an estimated $233K.
WESPAC Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 9 quarters.
WESPAC Advisors's Regeneron Pharmaceuticals position peaked at $731K in Q4 2015.
1,391 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.

Based on WESPAC Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.